Get the Stockscreener App
2.81
7.66%
0.20
After Hours:
2.87
0.06
+2.14%
MAIA Biotechnology Inc stock is traded at $2.81, with a volume of 82,724.
It is up +7.66% in the last 24 hours and down -7.57% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$2.61
Open:
$2.6
24h Volume:
82,724
Relative Volume:
0.60
Market Cap:
$63.35M
Revenue:
-
Net Income/Loss:
$-19.77M
P/E Ratio:
-1.7898
EPS:
-1.57
Net Cash Flow:
$-13.07M
1W Performance:
-1.06%
1M Performance:
-7.57%
6M Performance:
+27.73%
1Y Performance:
+27.73%
1-Day Range:
$2.5884
$2.885
1-Week Range:
$2.5101
$2.90
52-Week Range:
$0.82
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
MAIA Biotechnology Inc Stock (MAIA) Latest News
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 7.8% - Defense World
Daiwa Securities Group Inc. Invests $82,000 in Haemonetics Co. (NYSE:HAE) - Defense World
Promising signs for MAIA’s telomere-targeting treatment - The Pharma Letter
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 8% - Defense World
THIO Combo Yields Survival Benefit in Advanced NSCLC - AJMC.com Managed Markets Network
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CAE - PR Newswire
MAIA Biotechnology Reports Promising Interim Results in Lung Cancer Treatment Study - Vancity Buzz
MAIA Biotechnology Inc’s latest rating changes from various analysts - Knox Daily
MAIA reports survival benefit in advanced lung cancer trial - Investing.com
MAIA Biotech releases Phase II results for THIO - The Pharma Letter
MAIA reports survival benefit in advanced lung cancer trial By Investing.com - Investing.com Australia
MAIA reports survival benefit in advanced lung cancer trial - Investing.com India
MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks
MAIA reports survival benefit in advanced lung cancer trial By Investing.com - Investing.com UK
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - StockTitan
MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.9% - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.9% - Defense World
MAIA Biotechnology Inc [MAIA] Investment Guide: What You Need to Know - Knox Daily
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Down 13.9% in August - MarketBeat
Lazertinib With Amivantamab Approved by FDA for Use in NSCLC - AJMC.com Managed Markets Network
Mather Group LLC. Increases Stock Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
32,487 Shares in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Acquired by Virtu Financial LLC - Defense World
Officials Provide Update on Phase 2 Trial of THIO Plus Cemiplimab in NSCLC - DocWire News
Investing in MAIA Biotechnology Inc (MAIA): What You Must Know - Knox Daily
Evaluating MAIA’s financial ratios for a profitable investment - US Post News
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy - openPR
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy - Barchart
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy - The Globe and Mail
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent - Business Wire
GeoVax Labs (NASDAQ:GOVXW) Shares Up 3.3% - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 6.1% - MarketBeat
Signature Bank (NASDAQ:SBNYP) Trading Down 14.3% - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 6.1% Higher - Defense World
MAIA Biotechnology - BioSpace
Keeping an Eye on MAIA Biotechnology Inc (MAIA) After Insider Trading Activity - Knox Daily
MAIA Biotechnology Inc (MAIA) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment - NEWSnet
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment - openPR
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment - News Channel Nebraska
The Globe and Mail - The Globe and Mail
TSX Buyback Index (TXBB) QuotePress Release - The Globe and Mail
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment - Marketscreener.com
IPO Watch: 3 New Stocks Worth a Strong Look - Yahoo Finance
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today - Quantisnow
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 2.3% - MarketBeat
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Cap:
|
Volume (24h):